KPIs & Operating Metrics(New)

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NovoCure (NVCR) Long-Term Debt Issuances (2016 - 2025)

NovoCure's Long-Term Debt Issuances history spans 8 years, with the latest figure at $100.0 million for Q3 2025.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $100.0 million in Q3 2025 year-over-year; TTM through Mar 2026 was $100.0 million, a 3.15% increase, with the full-year FY2025 number at $100.0 million, up 3.15% from a year prior.
Long-Term Debt Issuances hit $100.0 million in Q3 2025 for NovoCure, up from $96.9 million in the prior quarter.
Over the last five years, Long-Term Debt Issuances for NVCR hit a ceiling of $100.0 million in Q3 2025 and a floor of $96.9 million in Q2 2024.